AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12,
November 06 2008 - 9:45AM
PR Newswire (US)
TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL, Inc. (AMEX:ADL), a leading
vertically-integrated pharmaceutical company with major operations
in China and the U.S., today announced its newly appointed Chairman
and CEO Mr. Douglas MacLellan will present at Rodman &
Renshaw's Annual Global Investment Conference taking place on
Wednesday, November 12th, 2008 at the New York Palace Hotel in New
York City. Mr. MacLellan will provide an informative overview of
AMDL's core business and growth strategy for its China specialty
pharmaceuticals, in-vitro diagnostics and cancer therapeutic
divisions. The Company has an aggressive and focused approach to
capitalize on these three market sectors, positioning AMDL as one
of most rapidly growing and highly-opportunistic micro-cap
investment prospects in the vertically-integrated, specialty
pharmaceutical sector. In 2008 alone, AMDL met numerous operational
milestones which include: securing more than $25 million in sales
contracts for its best-selling HPE anti-aging product line;
expanding AMDL's overall revenue opportunity for HPE by launching
additional HPE product formulations; and successfully securing US
FDA clearance for AMDL's ELISA DR-70(R) FDP cancer diagnostic test.
The ELISA DR-70(R) FDP cancer diagnostic test is the first test to
be cleared by the US FDA in over 25 years for the monitoring of
colorectal cancer. Attendees wishing to learn more about the
Company can attend Mr. MacLellan's presentation which is scheduled
at 9:55 a.m. EST in the Henry Salon, 5th Floor of the New York
Palace Hotel. Additionally, interested investors can visit the
Company's corporate website at http://www.amdl.com/ or contact
AMDL's investor relations department at 206.310.5323. About AMDL:
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi,
and Jilin, China, AMDL, Inc., along with its subsidiary Jade
Pharmaceutical Inc. (JPI), is a vertically integrated
bio-pharmaceutical company devoted to the research, development,
manufacturing, and marketing of diagnostic, pharmaceutical,
nutritional supplement, and cosmetic products. The company employs
over 400 people in the U.S. and China. The Company has an
additional 4 pharmaceutical and diagnostic products under review by
various regulatory authorities. Forward Looking Statements: Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995: The statements contained in this document include certain
predictions and projections that may be considered forward-looking
statements under securities law. These statements involve a number
of important risks and uncertainties that could cause actual
results to differ materially including, but not limited to, the
performance of joint venture partners, as well as other economic,
competitive and technological factors involving the Company's
operations, markets, services, products, and prices. With respect
to AMDL, Inc., except for the historical information contained
herein, the matters discussed in this document are forward-looking
statements involving risks and uncertainties that could cause
actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
related to the Company's access to additional capital, competition
and dependence on key management. AMDL Contact: Kristine Szarkowitz
Director-Investor Relations (206) 310-5323 DATASOURCE: AMDL, Inc.
CONTACT: Kristine Szarkowitz, Director-Investor Relations of AMDL,
Inc., +1-206-310-5323, Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024